EUVIMEDEUVIMED entdecken
Crossref

68 Ga-FAPI PET/CT for Differentiation of Malignant Peripheral Nerve Sheath Tumors, Neurofibromas, and Schwannomas

Anna-Maria Spektor, Marius Fried, Sergio A Zapata Bonilla, Ahmed Othman, Darius Kalasauskas, David Kersting, Philipp Mildenberger, Erik Winter, Stefanie Zimmer, Bonny Adami, Rainer Hamacher, Anne-Marie Waldschütz und 10 weitere

Journal of Nuclear Medicine · 2026-11 · 67 (11) · 1725-1733

DOI: 10.2967/jnumed.126.272348 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Journal of Nuclear Medicine, online erschienen am 20.08.2026. Verfasst von Anna-Maria Spektor und 21 weiteren Autor:innen. Beteiligte Einrichtung: Department of Nuclear Medicine, University Hospital Mainz, Mainz, Germany; anna-maria.spektor@unimedizin-mainz.de. Hauptthemen laut MEDLINE: Neurilemmoma, Positron Emission Tomography Computed Tomography, Neurofibroma, Nerve Sheath Neoplasms. Die Arbeit nennt 33 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Malignant peripheral nerve sheath tumors (MPNSTs) are aggressive soft-tissue sarcomas that can develop either de novo or as a result of malignant transformation of neurofibromas. Diagnostic modalities of choice, such as MRI or 18F-FDG PET/CT, show high sensitivity for the detection of MPNSTs but moderate specificity, as MPNSTs and benign peripheral nerve sheath tumors (BPNSTs) can initially present similar clinical and radiologic pictures. PET/CT with 68Ga-labeled fibroblast activation protein inhibitor (68Ga-FAPI) showed specific uptake in sarcomas and enabled differentiation of benign and malignant lesions in other entities. Here, we analyzed the ability of 68Ga-FAPI PET/CT to differentiate between MPNSTs and BPNSTs.

Methods

Twenty-six patients with suspected or histologically confirmed peripheral nerve sheath tumors who were scheduled to have surgical resection/biopsy underwent 68Ga-FAPI-46 PET/CT with static and dynamic acquisition. SUVmax, SUVmean, maximum and mean tumor-to-background ratios, and time-activity curves were evaluated using volume-of-interest-based analysis (isocontour 50%). Time to peak was derived from time-activity curves. Statistical analyses were performed, and receiver-operating-characteristic curves were calculated. Exemplary target validation by fibroblast activation protein immunohistochemistry was performed in 13 cases.

Results

Eighteen patients (4 with MPNSTs, 5 with neurofibromas, 9 with schwannomas) were included in the final analysis. MPNSTs showed significantly higher 68Ga-FAPI uptake compared with BPNSTs. Neurofibromas showed higher 68Ga-FAPI uptake compared with schwannomas. In dynamic imaging, time to peak of MPNSTs and neurofibromas was prolonged compared with schwannomas. Analysis of receiver-operating-characteristic curves displayed high sensitivity (100%) and specificity (92.86%) of 68Ga-FAPI PET/CT for discrimination of MPNSTs and BPNSTs, for an exploratory SUVmax cutoff value of 7.53. Fibroblast activation protein expression was strong in MPNSTs and moderate in BPNSTs.

Conclusion

68Ga-FAPI PET/CT may aid in differentiating between MPNSTs and BPNSTs, thereby improving lesion characterization in indeterminate MRI or 18F-FDG PET/CT scenarios.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

NeurilemmomaPositron Emission Tomography Computed TomographyNeurofibromaNerve Sheath NeoplasmsHumansDiagnosis, DifferentialFemaleMaleMiddle AgedAdultAgedGallium RadioisotopesFibroblast Activation Protein AlphaEndopeptidasesYoung AdultQuinolines

Stichwörter der Autor:innen

FAPI PET/CTMPNSTneurofibromaperipheral nerve sheath tumorsschwannoma

Substanzen

68Ga-FAPIGallium RadioisotopesFibroblast Activation Protein AlphaEndopeptidasesQuinolines

Autor:innen und Institutionen

  • Department of Nuclear Medicine, University Hospital Mainz, Mainz, Germany; anna-maria.spektor@unimedizin-mainz.de.
  • 3rd Medical Department, University Medical Center Mainz, Mainz, Germany.
  • University Cancer Center, University Medical Center Mainz, Mainz, Germany.
  • Department of Neuroradiology, University Medical Center Mainz, Mainz, Germany.
  • Department of Neurosurgery, University Hospital LMU Munich, Munich, Germany.
  • Department of Neurosurgery, University Medical Center Mainz, Mainz, Germany.

Zitieren

APA

Spektor, A. M., Fried, M., Zapata Bonilla, S. A., Othman, A., Kalasauskas, D., Kersting, D., Mildenberger, P., Winter, E., Zimmer, S., Adami, B., Hamacher, R., Waldschütz, A. M., Eckert, C., Conrad, J., Sommer, C., Herrmann, K., Fendler, W. P., Brockmann, M. A., Schreckenberger, M., …, & Röhrich, M. (2026). 68 Ga-FAPI PET/CT for Differentiation of Malignant Peripheral Nerve Sheath Tumors, Neurofibromas, and Schwannomas. Journal of Nuclear Medicine, 67(11), 1725-1733. https://doi.org/10.2967/jnumed.126.272348

Vancouver

Spektor AM, Fried M, Zapata Bonilla SA, Othman A, Kalasauskas D, Kersting D, et al. 68 Ga-FAPI PET/CT for Differentiation of Malignant Peripheral Nerve Sheath Tumors, Neurofibromas, and Schwannomas. Journal of Nuclear Medicine. 2026;67(11):1725-1733. doi:10.2967/jnumed.126.272348

BibTeX
@article{Spektor2026,
  author = {Spektor, Anna-Maria and Fried, Marius and Zapata Bonilla, Sergio A and Othman, Ahmed and Kalasauskas, Darius and Kersting, David and Mildenberger, Philipp and Winter, Erik and Zimmer, Stefanie and Adami, Bonny and Hamacher, Rainer and Waldschütz, Anne-Marie and Eckert, Christoph and Conrad, Jens and Sommer, Clemens and Herrmann, Ken and Fendler, Wolfgang P and Brockmann, Marc A and Schreckenberger, Mathias and Haberkorn, Uwe and Kindler, Thomas and Röhrich, Manuel},
  title = {68 Ga-FAPI PET/CT for Differentiation of Malignant Peripheral Nerve Sheath Tumors, Neurofibromas, and Schwannomas},
  journal = {Journal of Nuclear Medicine},
  year = {2026},
  volume = {67},
  number = {11},
  pages = {1725--1733},
  doi = {10.2967/jnumed.126.272348}
}
Kostenlos starten →